NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased Maravai securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

NEW YORK, March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=138831&fr ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Maravai LifeSciences To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW Y ...

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1] Allegations Against Defendants - The complaint alleges that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is claimed that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The lawsuit states that Maravai's goodwill was overstated [2] - As a result of these issues, the positive statements made by the Defendants about the company's business and prospects were materially misleading [2] Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3] - The lead plaintiff selects counsel to represent the class, and their ability to recover is not affected by the decision to serve as a lead plaintiff [3] Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4] - The firm aims to protect investors and consumers from fraud and negligence by businesses [4]

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Maravai ...

Lead Plaintiff Deadline is May 5, 2025CLICK HERE TO PROVIDE CONTACT INFORMATION AND JOIN THE CASENEW YORK, March 25, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI) on behalf of all persons and entities that purchased or otherwise acquired Maravai securities between August 7, 2024 and February 24, 2025, both dates inclusive ...

Core Viewpoint - A class action securities lawsuit has been filed against Maravai LifeSciences Holdings, Inc. due to alleged securities fraud affecting investors between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the Company's business and prospects [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Group 1 - Maravai LifeSciences Holdings, Inc. held its Q4 2024 earnings conference call on March 20, 2025, with key participants including CEO Trey Martin and CFO Kevin Herde [1][3] - The call included a formal presentation followed by a question and answer session, indicating an interactive format for discussing financial results [2][3] - The agenda for the call was outlined in the presentation slides, which were made available on the company's investor relations website [3] Group 2 - Management indicated that forward-looking statements would be made during the call, along with references to both GAAP and non-GAAP financial measures [4] - The company provided reconciliations to the most directly comparable GAAP measures in their press release and on their investor website [4]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $57 million, aligning with expectations, and full year revenues of $259 million, near the midpoint of the previously stated range of $255 million to $265 million [12][13] - GAAP net loss before non-controlling interests was $46 million for Q4 2024, compared to a loss of $110 million in Q4 2023, while the full year net loss was $260 million, up from $138 million in 2023 [15][16] - Adjusted EBITDA for Q4 2024 was a negative $1 million, down from $21 million in Q4 2023, with full year adjusted EBITDA at $36 million, reflecting a margin of 14% [15][17] Business Line Data and Key Metrics Changes - The biologic safety testing segment generated $15 million in Q4 and $63 million for the full year, with an adjusted EBITDA margin of about 70% [12][24] - The nucleic acid production segment had revenues of $42 million in Q4, including $14 million from high-volume CleanCap, and full year revenues of $196 million with an adjusted EBITDA margin of 26% [13][23] Market Data and Key Metrics Changes - Revenue breakdown by customer type for 2024 showed 48% from biopharma, 25% from life science and diagnostics, and 18% through distributors [14] - The company reported $13.6 million in revenue from China for the full year, with expectations for flat growth in 2025 [98][100] Company Strategy and Development Direction - The company is focused on returning its base business to growth, projecting revenues of $185 million to $205 million for 2025, excluding high-volume CleanCap [27][30] - Strategic investments include expanding commercial footprint and intellectual property protection while managing costs [31][45] - Recent acquisitions are expected to enhance capabilities in DNA and RNA design and discovery, positioning the company for future growth [48][62] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in forecasting due to market dynamics but expressed confidence in the company's assets and growth potential [25][26] - The company is enhancing visibility into customer clinical programs to improve sales forecasting accuracy [42][53] Other Important Information - The company ended 2024 with $322 million in cash and $300 million in long-term debt, resulting in a net cash position of $22 million [18][19] - Capital expenditures for 2024 were $30 million, with expectations for a decline to $15 million to $20 million in 2025 [20][33] Q&A Session Summary Question: Can you provide insights on profitability and gross margins for 2025? - Management indicated that the cost structure for 2025 will remain consistent with 2024, with fixed costs around $200 million and variable costs ranging between 10% and 12% [66][68] Question: How is the company improving visibility with key customers? - Management noted that new agreements include mandatory disclosure requirements for clinical trial milestones, which should enhance visibility [75][77] Question: What are the expectations for segment growth and market assumptions? - Management expects Q1 revenues to be slightly up from Q4 2024, with growth driven by GMP programs and the integration of recent acquisitions [80][83] Question: What are the capital allocation priorities for 2025? - The company plans to focus on reducing cash interest expenses and is open to M&A opportunities that align with their strategic goals [88][90] Question: How does the company view its exposure to NIH funding changes and growth in China? - Management does not anticipate significant headwinds from NIH funding changes and expects flat growth in China for 2025 [97][100]

NASDAQ: MRVI Q4 and Year-end 2024 Financial Results 01 Welcome Deb Hart, Head of Investor Relations 02 10-K Update, Financial Results & Guidance Kevin Herde, Chief Financial Officer 03 Business Highlights & Strategy Trey Martin, Chief Executive Officer 04 Q&A Session Trey Martin, Chief Executive Officer Kevin Herde, Chief Financial Officer © 2025 Maravai LifeSciences 2 Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains, and our officers and representatives may, from ...